We advised GH Research on the offering

Davis Polk advised GH Research PLC in connection with its $117.5 million SEC-registered offering of ordinary shares. The ordinary shares are listed on the Nasdaq Global Market under the ticker symbol “GHRS.”

GH Research is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression. The company’s initial focus is on developing its novel and proprietary mebufotenin therapies for the treatment of patients with treatment-resistant depression.

The Davis Polk corporate team included partners Deanna L. Kirkpatrick and Yasin Keshvargar and counsel Steven Glendon. Partner David R. Bauer and associates Shreya R. Kundur and Anne Kim provided intellectual property advice. Special counsel Mario J. Verdolini and associate Afrika Nora Owes provided tax advice. All members of the Davis Polk team are based in the New York office.

Copy link to share post